Lee Ainslie Abb Vie Inc. Transaction History

Maverick Capital LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $811,292 - $939,189	6,073 New	6,073 $905,000
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $1.25 Million - $1.59 Million	-11,681 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $276,427 - $313,786	-2,598 Reduced 18.19%	11,681 $1.26 Million
Q2 2021 Aug 16, 2021	BUY	$105.21 - $117.21 $1.5 Million - $1.67 Million	14,279 New	14,279 $1.61 Million
Q1 2021 May 17, 2021	SELL	$102.3 - $112.62 $635,283 - $699,370	-6,210 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$80.49 - $108.67 $337,092 - $455,109	4,188 Added 207.12%	6,210 $665,000
Q3 2020 Nov 16, 2020	BUY	$85.91 - $100.83 $173,710 - $203,878	2,022 New	2,022 $177,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.